01724nz a2200265n 4500 sh2007005971 DLC 20091104074147.0 070731i| anannbabn |a ana c sh2007005971 Uk eng DLC Rimonabant Acomplia (Trademark) Rimonabant hydrochloride Rimoslim Riobant Slimona SR141716 Zimulti (Trademark) g Pyrazoles g Weight loss preparations Work cat.: Pi-Sunyer, F.X. Biography of Rimonabant, 2007. Journal of the American College of Cardiology, vol. 47 (2006): pp. 1919-1926 (Rimonabant: a cannabinoid receptor type 1 blocker for management of multi cardiometabolic risk factors) Drugs today, Aug. 2005: pp.499-508 (Rimonabant hydrochloride, the first drug in a new class of selective cannabinoid type 1 (CB1) receptor antagonists, is showing promise in clinical trials for the treatment of obesity and related metabolic risk factors, in addition to tobacco dependence) Wikipedia, 31 July 2007: Rimonabant (Rimonabant (also known as SR141716, Acomplia, Riobant, Slimona, Rimoslim, and Zimulti) is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Rimonabant is currently being sold in the United Kingdom by Sanofi-Aventis and in Denmark by Sanofi-Synthelabo under the trade name Acomplia (which is the name used in 18 countries, as of 2007). Riobant, Slimona and Rimoslim are generic forms available in India. If approved in the United States, it is intended to be marketed under the name Zimulti)